

Oral Sessions

Saturday, September 13, 2008, 09:10 – 11:15 hrs

Session: 07 Glioblastoma multiforme (I)
Room: Auditorium
Time: 09:10 - 10:10 hrs
Speaking time: 8´+2´
Chair: M. Van den Bent (The Netherlands), C. Balañà (Spain)

O37

Early treatment related necrosis is associated with prolonged survival in malignant gliomas

A. M. Demopoulos¹, B. A. Napolitano², D. Chalif³, K. Black⁴;

¹Division of Neuro-Oncology, Dept. of Neurology, Manhasset, NY, United States, ²Biostatistics Unit, Feinstein Institute for Medical Research, Manhasset, NY, United States, ³Department of Neurosurgery, Manhasset, NY, United States, ⁴Division of Neuro-Radiology, Dept. of Radiology, Manhasset, NY, United States.

O38

Impact of extent of resection and outcome to adjuvant chemotherapy. A meta-analysis of three EORTC studies

M. J. van den Bent¹, R. Stupp², J. Hildebrand³, A. A. Brandes⁴, R. Mirimanoff⁵, W. Mason⁶, M. Weller⁷, J. G. Cairncross⁸, J. Delattre⁹, D. Lacombe¹⁰, T. Gorlia¹⁰;

¹Daniel den Hoed Cancer Center, Rotterdam, The Netherlands, ²Multidisciplinary Oncology Center, University of Lausanne Hospitals, Lausanne, Switzerland, ³Hopital Universitaire Erasme, Brussels, Belgium, ⁴Medical Oncology Department, Bellaria-Maggiore Hospital, Bologna, Italy, ⁵Dept Radiotherapy, University of Lausanne Hospitals, Lausanne, Switzerland, ⁶St Margaret Hospital, Toronto, ON, Canada, ⁷University Hospital Zurich, Zurich, Switzerland, ⁸University of Calgary, Calgary Health Region, Calgary, AB, Canada, ⁹Service de Neurologie Mazarin Hôpital de la Salpêtrière, Paris, France, ¹⁰EORTC HeadQuarters, Brussels, Belgium.

O39

Hypofractionated radiotherapy with Intensity Modulated Arc Therapy (IMAT) plus adjuvant temozolomide for primary glioblastoma multiforme

N. D'Abbiere¹, A. Pisanello², G. De Bert³, C. Iotti¹, T. Palmieri¹, D. Ramundo¹, M. Galeandro¹, M. Ruggieri¹, S. Riccardi⁴, D. Lambertini⁴, N. Bizzocchi⁴, R. Ghadirpour⁵, L. Armaroli¹, N. Marcello²;

¹Radiotherapy Unit, Reggio Emilia, Italy, ²Neurology Unit, Reggio Emilia, Italy, ³Neuro-Radiology Unit, Reggio Emilia, Italy, ⁴Medical Physics, Reggio Emilia, Italy, ⁵Neuro-Surgery Hub-Spke Parma-Reggio Emilia, Reggio Emilia, Italy.

O40

Prospective randomized study comparing first-line nitrosourea-based chemotherapy versus radiotherapy alone in non resectable glioblastomas in adult

M. Frenay¹, J. Simon², L. Benboubker³, L. Taillandier⁴, D. Castera⁵, M. Campone⁶, A. Busson⁷, F. Berger⁸, C. Lebrun⁹;

¹CAL, Nice, France, ²Hopital Salpetriere, Paris, France, ³Hopital Bretonneau, Tours, France, ⁴Hopital Central, Nancy, France, ⁵Clinique St Pierre, Perpignan, France, ⁶Centre Gauducheau, Saint Herblain, France, ⁷Centre Baclesse, Caen, France, ⁸Chu Grenoble, Grenoble, France, ⁹CHU, Nice, France.

O41

Phase I/II Study of Enzastaurin (ENZ) plus Temozolomide (TMZ) and Radiation Therapy (XRT) in Patients (Pts) with Glioblastoma Multiforme (GBM) or Gliosarcoma (GS)

N. Butowski¹, K. Lamborn¹, S. Chang¹, M. Page¹, R. Parvataneni¹, S. Chang², A. M. Liepa², S. Nico², D. Thornton², M. Prados¹;

¹University of California, San Francisco, San Francisco, CA, United States, ²Eli Lilly and Company, Indianapolis, IN, United States.

O42

Radiochemotherapy with daily concomitant and adjuvant one week on/one week off temozolomide plus indomethacin in newly diagnosed glioblastoma: a phase II trial

M. Weiler¹, C. Hartmann², D. Wiewrodt³, U. Herrlinger⁴, M. Bamberg⁵, A. von Deimling¹, M. Weller⁶, W. Wick¹;

¹University of Heidelberg, Heidelberg, Germany, ²German Cancer Research Center, Heidelberg, Germany, ³University of Mainz, Mainz, Germany, ⁴University of Bonn, Bonn, Germany, ⁵University of Tübingen, Tübingen, Germany, ⁶University of Zurich, Zurich, Switzerland.

Session: 08 Cell signaling and biomolecular markers

Room: Sala J

Time: 09:10 - 10:10 hrs

Speaking time: 8´+2´

Chair: A.Von Deimling (Germany), M.Robledo (Spain)

O43

The topography of cellular malignancy in human glioblastoma

M. Glas¹, B. H. Ley², A. Leinhaas², R. Eisenreich³, B. Steinfarz², J. Schramm⁴, M. Simon⁴, U. Herrlinger⁵, O. Brüstle², B. Scheffler³;

¹Clinical Neurooncology Unit and Insitute for Reconstructive Neurobiology, Stem Cell Pathologies Group, University of Bonn, Bonn, Germany, ²Insitute for Reconstructive Neurobiology, University of Bonn, Bonn, Germany, ³Insitute for Reconstructive Neurobiology, Stem Cell Pathologies Group, University of Bonn, Bonn, Germany, ⁴Dept. of Neurosurgery, University of Bonn, Bonn, Germany, ⁵Clinical Neurooncology Unit, University of Bonn, Bonn, Germany.

O44

Identification of relevant markers for the classification and grading of diffusely infiltrative gliomas

Y. Ruano¹, T. Ribalta², A. Rodríguez de Lope¹, C. Fiaño³, E. Pérez-Magán¹, J. Hernández-Moneo¹, Y. Campos-Martín¹, J. García⁴, M. Mollejo¹, **B. Meléndez¹**;

¹Hospital Virgen de la Salud, Toledo, Spain, ²Hospital Clinic, Barcelona, Spain, ³Complejo Hospitalario Xeral-Cíes, Vigo, Spain, ⁴MD Anderson Internacional, Madrid, Spain.

O45

Conversion of astrocytes into progenitor-like cells upon Transforming Growth Factor alpha (TGFA) exposure sensitizes them to cancerous transformation

C. Dufour¹, J. Cadusseau², P. Varlet¹, N. Auger¹, E. Daudigeos¹, P. Rodier¹, A. Dias-Morais³, G. Vassal¹, H. Chneiweiss³, M. Junier⁴;

¹Gustave Roussy, Villejuif, France, ²Inserm U841, Créteil, France, ³Inserm UMR 894, Paris, France, ⁴Hospital Sainte-Anne, Paris, France.

O46

The response of Human Glioma cells to Temozolomide and Irradiation: Relationship with MGMT promotor methylation and protein expression

P. Sminia¹, K. A. van Niffterik¹, J. van den Berg¹, N. Ameziane¹, T. J. M. Hulsebos², S. Leenstra², L. Wedekind¹, M. V. M. Lafleur¹, L. J. A. Stalpers², B. J. Slotman¹;

¹VU University Medical Center, Amsterdam, The Netherlands, ²Academic Medical Center, Amsterdam, The Netherlands.

O47

Temozolomide induces selective depletion of cancer stem cells in human glioblastomas

D. Beier¹, S. Röhrl¹, D. R. Pillai¹, S. Schwarz¹, L. Kunz-Schughart², M. Proescholdt³, A. Brawanski³, U. Bogdahn¹, J. Wischhusen⁴, G. Reifenberger⁵, P. Hau¹, C. P. Beier¹;

¹Department of Neurology, Regensburg, Germany, ²ZIK, OnkoRay, Dresden, Germany, ³Department of Neurosurgery, Regensburg, Germany, ⁴Interdisciplinary Center for Clinical Research, Würzburg, Germany, ⁵Department of Neuropathology, Düsseldorf, Germany.

O48

Concordance between serum DNA and tumor DNA in detection of genetic-epigenetic aberrations of glial tumors

I. Lavon, M. Raphael, J. Goldmann, B. Zelikovitch, **T. Siegal**;
Hadassah Hebrew University Hospital, Jerusalem, Israel.

Session: 09 Neurological complications of systemic cancer

Room: Sala F

Time: 09:10 - 10:10 hrs

Speaking time: 8' + 2'

Chair: R.Soffiatti (Italy), S.Vilà (Spain)

O49

Increased risk of stroke and transient ischemic attack (TIA) in 5-year survivors of Hodgkin's Lymphoma

L. D. Dorresteijn¹, M. L. De Bruin², M. B. van 't Veer³, E. M. Noordijk⁴, H. van den Berg⁵, B. M. Aleman², A. C. Kappelle¹, W. Booger², F. E. van Leeuwen²;

¹Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, ²Netherlands Cancer Institute, Amsterdam, The Netherlands, ³Erasmus MC/ Daniel den Hoed Center, Rotterdam, The Netherlands, ⁴Leiden University Medical Center, Leiden, The Netherlands, ⁵Emma Children's Hospital, Amsterdam, The Netherlands.

O50

Optic neuropathy in patients with malignant gliomas treated with bevacizumab

J. H. Sherman¹, D. G. Aregawi¹, A. La², S. S. Rosenfeld³, H. M. Fathallah-Shaykh⁴, J. M. Larner¹, S. A. Newman¹, **D. Schiff**¹;

¹University of Virginia, Charlottesville, VA, United States, ²University of California, Los Angeles, Los Angeles, CA, United States, ³Columbia University, New York, NY, United States, ⁴Rush University, Chicago, IL, United States.

O51

Comparison of the retrospective and prospective BSBM system's classification with a 6 years follow up for patients with brain metastases treated by Leksell Gamma Knife radiosurgery

D. Devriendt^{1,2}, F. De Smedt¹, P. David³, N. Massager⁴;

¹Institut Jules bordet, Brussels, Belgium, ²Gamma Knife Center of ULB, Brussels, Belgium, ³Erasmie Hospital, Brussels, Belgium, ⁴Gamma knife center of ULB, Brussels, Belgium.

O52

Impact of Surgical Excision Methodology on the Incidence of Local Recurrence in Patients with Single Brain Metastasis (SBM) Who Have Not Received Adjuvant Whole Brain Radiation Therapy (AWBRT)

D. Suki¹, A. J. Patel², M. A. Hatiboglu¹, H. Abou-Assi¹, R. Sawaya¹;

¹MD Anderson Cancer Center, Houston, TX, United States, ²Baylor College of Medicine, Houston, TX, United States.

O53

Differential impact of whole brain radiotherapy added to radiosurgery for the RPA class I or II brain metastases

D. Kong, J. Lee, Y. Im, D. Nam, K. Park, J. Kim;

Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

O54

Phase II trial of patupilone in patients with breast cancer brain metastases

D. M. Peereboom¹, A. K. Conlin², A. D. Seidman², C. Brewer¹;

¹Cleveland Clinic, Cleveland, OH, United States, ²Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Session: 10 Glioblastoma multiforme (II)

Room: Auditorium

Time: 10:15 - 11:15 hrs

Speaking time: 8' + 2'

Chair: L.Salford (Sweden), J.De Campos (Spain)

O55

Molecular stereotactic biopsies in gliomas - a prospective one-year experience

C. A. Eroes¹, N. Thon¹, E. Grasbon-Frod², G. Poepper³, J. Tonn¹, F. Kreth¹;

¹Klinikum Grosshadern, Neurosurgical Department, Munich, Germany, ²Klinikum Grosshadern, Neuropathological Institute, Munich, Germany, ³Klinikum Grosshadern, Nuclear Medicine Department, Munich, Germany.

O56

Integration of metabolic imaging and molecular genetic profiling of serial stereotactic biopsies are valuable for histological discrimination of oligodendrogliomas, mixed oligoastrocytomas and astrocytomas WHO° II/III

N. Thon¹, C. Erös¹, G. Pöpper², J. Herms³, J. Tonn¹, F. Kreth¹;

¹Department of Neurosurgery, Munich, Germany, ²Department of Nuclear Medicine, Munich, Germany, ³Institute of Neuropathology, Munich, Germany.

O57

Primary Glioblastoma treated with Boron Neutron Capture Therapy - Evaluation of a prolonged high dose of boronophenylalanine (BPA)

R. Henriksson¹, J. Capala^{2,3}, A. Michanek⁴, S. Lindahl⁵, L. G. Salford⁶, L. Franzén¹, E. Blomquist⁷, J. Westlin⁸, T. A. Bergenheim⁹;

¹Dept of Radiation Science, Umeå University, Umeå, Sweden, ²Studsvik Medical Co, Nyköping, Sweden, ³Unit for Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden, ⁴Dept of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁵Dept of Oncology, Karlstad Central Hospital, Karlstad, Sweden, ⁶Dept of Neurosurgery and Radiation Physics, Lund University Hospital, Lund, Sweden, ⁷Dept of Radiation Oncology, Uppsala University Hospital, Uppsala, Sweden, ⁸Dept of Oncology, Central Hospital, Eskilstuna, Sweden, ⁹Dept of Neurosurgery, Umeå University, Umeå, Sweden.

O58

Survival benefit from Boron Neutron Capture Therapy for the newly diagnosed glioblastoma patients

N. Nonoguchi¹, S. Kawabata¹, S. Miyatake¹, K. Iida¹, S. Miyata¹, K. Yokoyama¹, T. Kuroiwa¹, M. Kirihata², Y. Imahori³, K. Ono⁴;

¹Osaka Medical College Hospital, Takatsuki, Japan, ²Osaka Prefectural University, Osaka, Japan, ³CICS Corporation, Tokyo, Japan, ⁴Kyoto University Research Reactor Institute, Sakai, Japan.

Saturday, September 13, 2008, 09:10 – 11:15 hrs

O59

Immunotherapy of glioblastoma with autologous dendritic cells

M. Sabel¹, M. Rapp¹, Z. Özcan², J. Fischer², J. Rox², R. Sorg²;

¹Department of Neurosurgery, Duesseldorf, Germany, ²Institute for Transplantation Diagnostics and Cell Therapeutics, Duesseldorf, Germany.

O60

Imaging and dosimetry of convection enhanced delivery of Cotara (¹³¹I-chTNT-1/B Mab) in patients with recurrent glioblastoma

K. D. Judy¹, R. Lustig¹, J. Lopinto¹, S. Shen², J. Fiveash², J. Shan³;

¹Univeresity of Pennsylvania, Philadelphia, PA, United States, ²Univeresity of Alabama, Birmingham, Birmingham, AL, United States, ³Peregrine Pharmaceuticals, Inc., Tustin, CA, United States.

Session: 11 Prognostic factors in brain tumors

Room: Sala J

Time: 10:15 - 11:15 hrs

Speaking time: 8´+2´

Chair: M.Preusser (Austria), A.Tortosa (Spain)

O61

Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy

C. Park¹, S. Lee², C. Kim¹, D. Kim², S. Paek¹, D. Kim¹, D. Heo², I. Kim³, H. Jung¹;

¹Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Republic of Korea, ²Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, ³Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.

O62

Quantitative, PCR-based MGMT-methylation analysis in glioblastoma multiforme

L. Mariani¹, L. Anderегgen¹, M. Arnold², I. Vajta², E. Vassella²;

¹Department of Neurosurgery, University Hospital Inselspital, Bern, Switzerland, ²Institute of Pathology, University of Berne, Bern, Switzerland.

O63

Prognostic and predictive significance of MGMT promoter methylation and protein expression in glioblastoma patients

S. Spiegl-Kreinecker¹, C. Pirker^{1,2}, M. Filipits², D. Lötsch^{1,2}, J. Buchroithner¹, J. Pichler³, R. Silye⁴, M. Micksche², J. Fischer¹, W. Berger²;

¹Department of Neurosurgery, Linz, Austria, ²Institute of Cancer Research, Department of Medicine I, Medical University, Vienna, Austria, ³Internal Medicine, Wagner Jauregg Hospital, Linz, Austria, ⁴Institute of Pathology and Neuropathology, Wagner Jauregg Hospital, Linz, Austria.

O64

Anti-MGMT immunohistochemistry in EORTC/NCIC trial 26981/22981: observer variability, lack of association with MGMT promoter methylation status and patient survival impede its use as clinical biomarker in glioblastoma multiforme. A translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

M. Preusser¹, R. C. Janzer², J. Felsberg³, G. Reifenberger³, R. Stupp⁴, T. Gorlia⁵, C. Marosi¹, H. Heinzl⁶, J. A. Hainfellner⁷, M. Hegi^{8,9};

¹Department of Internal Medicine 1, Medical University of Vienna, Vienna, Austria, ²Department of Neurology and Division of Neuropathology, Center Hospitalier Universitaire Vaudois, Lausanne, Switzerland, ³Department of Neuropathology, Heinrich-Heine-University, Düsseldorf, Germany, ⁴Multidisciplinary Oncology Center, Center Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland, ⁵Data Center, European Organization for Research and Treatment of Cancer, Brussels, Belgium, ⁶Core Unit for Medical Statistics and Informatics, Medical University of Vienna, Vienna, Austria, ⁷Institute of Neurology, Medical University of Vienna, Vienna, Austria, ⁸Laboratory of Tumor Biology and Genetics, Centre, University Romand de Neurochirurgie Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland, ⁹National Center of Competence in Research Molecular Oncology, Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland.

O65

Association between immunohistochemical tissue inhibitor of metalloproteinases-1 (TIMP-1) score and patient survival in gliomas

C. Aaberg-Jessen¹, K. Christensen¹, H. D. Schrøder¹, H. Offenber², N. Brønner², **B. W. Kristensen**¹;

¹Department of Pathology, Odense University Hospital, Odense, Denmark, ²Department of Veterinary Pathobiology, Univ. of Copenhagen, Copenhagen, Denmark.

O66

Prognostic significance of NDRG2 promoter hypermethylation in atypical and anaplastic meningiomas

A. Tortosa¹, J. Bruna², P. Roerig³, F. Martínez¹, M. Riemenschneider³, S. Boluda⁴, P. Giménez-Bonafé⁵, G. Reifenberger³;

¹Department of Basic Nursing, University of Barcelona, Barcelona, Spain, ²Servicio de Neurología, Hospital de Bellvitge, Barcelona, Spain, ³Department of Neuropathology, Heinrich-Heine-University, Düsseldorf, Germany, ⁴Institut de Neuropatologia, Hospital de Bellvitge, Barcelona, Spain, ⁵Departament de Ciències Fisiològiques II, University of Barcelona, Barcelona, Spain.

Session: 12 Quality of life studies

Room: Sala F

Time: 10:15 - 11:15 hrs

Speaking time: 8´+2´

Chair: R.Grant (United Kingdom), E.Verger (Spain)

O67

Health-related quality of life of long-term surviving high-grade glioma patients

i. bosma, J. C. Reijneveld, L. Douw, M. J. Vos, T. J. Postma, W. P. Vandertop, B. J. Slotman, M. J. B. Taphoorn, J. J. Heimans, M. Klein;

VU University Medical Center, Amsterdam, The Netherlands.

O68

Cognitive rehabilitation of glioma patients: The results of a prospective, randomized study

K. Gehring¹, N. K. Aaronson^{2,3}, M. M. Sitskoorn^{1,4}, M. Klein⁵, T. J. Postma⁵, M. J. van den Bent⁶, G. N. Beute⁷, R. H. Enting⁸, A. C. Kappelle⁹, W. Boogerd¹⁰, T. Veninga¹¹, A. Twijnstra¹², D. H. Boerman¹³, M. J. B. Taphoorn^{14,15};

¹Rudolf Magnus Institute of Neuroscience / UMC Utrecht, Utrecht, Netherlands, ²the Netherlands Cancer Institute, Amsterdam, Netherlands, ³University of Amsterdam, Amsterdam, Netherlands, ⁴Tilburg University, Tilburg, Netherlands, ⁵VU University Medical Center, Amsterdam, Netherlands, ⁶Erasmus MC, Rotterdam, Netherlands, ⁷St. Elisabeth Hospital, Tilburg, Netherlands, ⁸University Medical Center Groningen, Groningen, Netherlands, ⁹Radboud University Nijmegen, Nijmegen, Netherlands, ¹⁰Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands, ¹¹Dr. Bernard Verbeeten Institute, Tilburg, Netherlands, ¹²University Hospital Maastricht, Maastricht, Netherlands, ¹³Rijnstate Hospital, Arnhem, Netherlands, ¹⁴Medical Centre Haaglanden, The Hague, Netherlands, ¹⁵VU University Medical Centre, Amsterdam, Netherlands.

O69

Survey on the hormonal system and fertility in women of reproductive age after receiving therapy for malignant glioma WHO III or IV

K. Elandt¹, C. Kurz², M. Hassler¹, U. Dieckmann³, A. Rottenfusser³, C. Marosi¹;

¹MUW, Depart. of Oncology, Vienna, Austria, ²MUW, Depart. of Gynaecology, Vienna, Austria, ³MUW; Depart. of Radiotherapy, Vienna, Austria.

O70

Attitudes to diagnosing and treating depression in glioma: a questionnaire survey of five specialties

A. G. Rooney¹, A. Carson², I. R. Whittle¹, S. Erridge¹, R. Grant¹;

¹Edinburgh Centre for Neuro-oncology, Edinburgh, United Kingdom, ²Royal Edinburgh Hospital, Edinburgh, United Kingdom.

O71

Endocrine function after craniospinal irradiation for medulloblastoma in children and adults.

S. Beltran¹, M. El Rawas¹, M. Sunyach², P. Berlier², C. Conter², F. Borson-Chazot³, **D. Frappaz**²;

¹Fédération d'Endocrinologie groupement hospitalier Est, Bron, France, ²Centre Léon Bérard, Lyon, France, ³Fédération d'Endocrinologie groupement hospitalier Est, Lyon, France.

O72

The impact of cognitive deficits and epilepsy on quality of life in meningioma patients after treatment.

M. L. Waagemans¹, M. Dijkstra¹, D. van Nieuwenhuizen¹, M. Wumkes², C. M. F. Dirven¹, J. C. Reijneveld¹, M. Klein¹, L. J. A. Stalpers²;

¹VU University Medical Center, Amsterdam, The Netherlands, ²AMC-University of Amsterdam, Amsterdam, The Netherlands.